IBDEI3DD ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,56645,0)
 ;;=E10.52^^261^2831^78
 ;;^UTILITY(U,$J,358.3,56645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56645,1,3,0)
 ;;=3^DM Type 1 w/ DM Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,56645,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,56645,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,56646,0)
 ;;=E10.610^^261^2831^75
 ;;^UTILITY(U,$J,358.3,56646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56646,1,3,0)
 ;;=3^DM Type 1 w/ DM Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,56646,1,4,0)
 ;;=4^E10.610
 ;;^UTILITY(U,$J,358.3,56646,2)
 ;;=^5002613
 ;;^UTILITY(U,$J,358.3,56647,0)
 ;;=E10.620^^261^2831^74
 ;;^UTILITY(U,$J,358.3,56647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56647,1,3,0)
 ;;=3^DM Type 1 w/ DM Dermatitis
 ;;^UTILITY(U,$J,358.3,56647,1,4,0)
 ;;=4^E10.620
 ;;^UTILITY(U,$J,358.3,56647,2)
 ;;=^5002615
 ;;^UTILITY(U,$J,358.3,56648,0)
 ;;=E10.621^^261^2831^80
 ;;^UTILITY(U,$J,358.3,56648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56648,1,3,0)
 ;;=3^DM Type 1 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,56648,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,56648,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,56649,0)
 ;;=E10.622^^261^2831^85
 ;;^UTILITY(U,$J,358.3,56649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56649,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,56649,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,56649,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,56650,0)
 ;;=E10.630^^261^2831^84
 ;;^UTILITY(U,$J,358.3,56650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56650,1,3,0)
 ;;=3^DM Type 1 w/ Peridontal Disease
 ;;^UTILITY(U,$J,358.3,56650,1,4,0)
 ;;=4^E10.630
 ;;^UTILITY(U,$J,358.3,56650,2)
 ;;=^5002619
 ;;^UTILITY(U,$J,358.3,56651,0)
 ;;=E10.641^^261^2831^82
 ;;^UTILITY(U,$J,358.3,56651,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56651,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,56651,1,4,0)
 ;;=4^E10.641
 ;;^UTILITY(U,$J,358.3,56651,2)
 ;;=^5002621
 ;;^UTILITY(U,$J,358.3,56652,0)
 ;;=E10.649^^261^2831^83
 ;;^UTILITY(U,$J,358.3,56652,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56652,1,3,0)
 ;;=3^DM Type 1 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,56652,1,4,0)
 ;;=4^E10.649
 ;;^UTILITY(U,$J,358.3,56652,2)
 ;;=^5002622
 ;;^UTILITY(U,$J,358.3,56653,0)
 ;;=E10.65^^261^2831^81
 ;;^UTILITY(U,$J,358.3,56653,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56653,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,56653,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,56653,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,56654,0)
 ;;=E11.40^^261^2831^90
 ;;^UTILITY(U,$J,358.3,56654,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56654,1,3,0)
 ;;=3^DM Type 2 w/ DM Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,56654,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,56654,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,56655,0)
 ;;=E11.42^^261^2831^93
 ;;^UTILITY(U,$J,358.3,56655,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56655,1,3,0)
 ;;=3^DM Type 2 w/ DM Polyneuropathy
 ;;^UTILITY(U,$J,358.3,56655,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,56655,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,56656,0)
 ;;=E11.43^^261^2831^86
 ;;^UTILITY(U,$J,358.3,56656,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56656,1,3,0)
 ;;=3^DM Type 2 w/ DM Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,56656,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,56656,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,56657,0)
 ;;=E11.49^^261^2831^88
 ;;^UTILITY(U,$J,358.3,56657,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,56657,1,3,0)
 ;;=3^DM Type 2 w/ DM Neurological Complications
 ;;^UTILITY(U,$J,358.3,56657,1,4,0)
 ;;=4^E11.49
